Core Viewpoint - 1H25 results were disappointing with a revenue decline of 0.8% YoY to RMB4.36 billion, while adjusted net profits to shareholders increased by 2.1% YoY to RMB1.36 billion, missing expectations [1][2] Revenue Performance - Revenue from legacy products TPIAO and EPO, which accounted for 54% and 16% of total revenue respectively, declined by 4% YoY and 12% YoY due to high base effects, stricter medical insurance controls, increased competition, and negative impacts from province-level VBP [2][3] - Revenue from Sunshine Guojian increased by 8% YoY, driven by its CDMO business, while sales from the alopecia area increased by 24% YoY, attributed to new SKUs and effective digital promotions [3] Profitability - Adjusted net profits to shareholders rose by 2.1% YoY to RMB1.36 billion, although management did not update guidance post-results, indicating challenges in meeting previous double-digit growth expectations [3] Future Developments - The company is closely monitoring Pfizer's development plan for 707, with a focus on its Phase II data in colorectal cancer to be presented at the 2025 ESMO conference [1][3] - Pfizer's near-term objectives include initiating global Phase III development for 707 in various cancers and exploring its potential in combination with Pfizer's ADC therapies [3] Pipeline Updates - The company anticipates new product approvals between 2026-28, including candidates for psoriasis, acute gouty arthritis, adult atopic dermatitis, and asthma, with several in late-stage trials [3] Sales Forecast Adjustments - Post-results, the company revised its 2025-27 sales forecasts, decreasing estimates for legacy products while increasing projections for Mandi due to strong sales momentum [3] - The target price was raised to HK$38.20 based on updated sales forecasts and a revised WACC from 10.6% to 9.7% [3]

Group 1 - Sangfor Pharmaceuticals (01530) saw a stock increase of 3.61%, reaching HKD 32.16, with a trading volume of HKD 584 million [1] - The company reported a revenue of RMB 4.4 billion for the first half of the year, a year-on-year decline of 0.8%, primarily due to a slowdown in TPIAO sales, although this was partially offset by strong growth in its hair loss treatment product line [1] - Net profit attributable to shareholders increased by 24.6% to RMB 1.1 billion, benefiting from a 49% reduction in financial costs [1] Group 2 - The company anticipates launching several new drugs between 2025 and 2026, including 608 (IL-17A inhibitor) and 613 (IL-1β inhibitor), which are expected to drive revenue growth [1] - The potential of 707 (PD-1/VEGF dual antibody) is highlighted as a candidate for becoming a blockbuster drug globally, with Pfizer expected to actively promote its global clinical development and combination therapy [1] - The initiation of global clinical trials for 707 is seen as a significant catalyst for the company's profit growth [1] Group 3 - According to Lyon, the performance of Sangfor Pharmaceuticals in the first half of the year was mixed, with weak TPO sales but strong Mandi sales driven by increased adoption of Mandi Foam and successful online distribution [2] - The overseas research progress of SSGJ-707 is anticipated to be a key catalyst, with Pfizer stating that global Phase III studies for non-small cell lung cancer will start by the end of 2025, along with further exploration in other tumor types [2]

Group 1 - The stock price of Sihuan Pharmaceutical has increased by over 3%, reaching HKD 32.16 with a trading volume of HKD 584 million [1] - Sihuan Pharmaceutical reported a revenue of RMB 4.4 billion for the first half of the year, a year-on-year decrease of 0.8%, primarily due to a slowdown in TPIAO sales, although this was partially offset by strong growth in its hair loss treatment product line [1] - The net profit attributable to shareholders increased by 24.6% to RMB 1.1 billion, benefiting from a 49% reduction in financial costs [1] Group 2 - The company expects to launch several new drugs between 2025 and 2026, including 608 (IL-17A inhibitor) and 613 (IL-1β inhibitor), which are anticipated to drive revenue growth [1] - The 707 (PD-1/VEGF dual antibody) is considered to have the potential to become a blockbuster drug globally, with Pfizer expected to actively promote its global clinical development and combination therapy [1] - The initiation of global clinical trials for 707 is expected to be a significant catalyst for the company's profit growth [1][2]

Core Viewpoint - Citi has significantly raised the profit forecasts for Sanofi Pharmaceutical (01530) for 2025 to 2027 by 288%, 44.6%, and 38.4%, respectively, leading to a target price increase from HKD 19.6 to HKD 37.1, maintaining an "outperform" rating [1] Group 1: Financial Projections - Profit forecasts for 2025, 2026, and 2027 are now projected at RMB 9.273 billion, RMB 4.171 billion, and RMB 4.689 billion, respectively [1] - The new target price corresponds to a forecasted price-to-earnings ratio of 18 times [1] Group 2: Performance Analysis - Sanofi Pharmaceutical's performance in the first half of the year showed mixed results, with TPO sales being weak while Mandi sales were strong, driven by increased adoption of Mandi Foam and successful online distribution [1] - The company anticipates that the overseas research progress of SSGJ-707 will be a key catalyst for growth [1] Group 3: Research and Development - According to Pfizer, SSGJ-707 is expected to initiate global Phase III studies for non-small cell lung cancer by the end of 2025, with further exploration into its application in other tumor types, including additional Phase I/II studies in combination with its antibody-drug conjugate portfolio [1]

Core Viewpoint - Citi has significantly raised its profit forecasts for 3SBio (01530) for 2025 to 2027 by 288%, 44.6%, and 38.4%, reaching RMB 9.273 billion, RMB 4.171 billion, and RMB 4.689 billion respectively, while increasing the target price from HKD 19.6 to HKD 37.1, implying a forecasted P/E ratio of 18 times, maintaining an "outperform" rating [1] Financial Performance - 3SBio's performance in the first half of the year showed mixed results, with TPO sales being weak while Mandi sales were strong, driven by increased adoption of Mandi Foam and successful online distribution [1] Key Catalysts - The ongoing overseas research progress of SSGJ-707 is expected to be a key catalyst for the company [1] - According to Pfizer, SSGJ-707 is set to initiate a global Phase III study for non-small cell lung cancer by the end of 2025, while further exploring its applications in other tumor types, including more Phase I/II studies in conjunction with its antibody-drug conjugate product portfolio [1]